UNSPSC 51332003: Paliperidone

This classification denotes an antipsychotic agent with the molecular formula C23H27FN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 838F01T721, chemically known as 4h-pyrido(2,1-a)pyrimidin-4-one, 6,7,8,9-tetrahydro-3-(2-(4-(6-fluro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-9-hydroxy-2-methyl- but generally known as paliperidone, which bears US NIH Compound Identifier 115237. European Medicines Agency schedules Paliperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23268.

UNSPSC 51332003 Paliperidone, a Commodity code, does not reflect the work state and local governments are actually procuring under this designation. The three recent opportunities tagged to this code involve naloxone and drug deactivation systems procurement, direct-to-manufacturer pharmacy benefit programs, and generic multi-source pharmaceuticals and OTC products — none of which align with paliperidone, an atypical antipsychotic medication. State and local health agencies, cooperative purchasing alliances, and county government health departments are the issuing bodies driving this activity, but the code as applied appears to be a taxonomy mismatch rather than a meaningful category for paliperidone itself.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries to the county community health building and including all shipping costs in vendor bids. The Texas Health and Human Services Commission released an RFI (HHS0017013) on April 3, 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, seeking vendor capacity for negotiated net pricing models and outcomes-based agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with contract awards effective July 1, 2026 and requiring vendors to work through three authorized wholesalers with specified insurance minimums and compliance with FDA, cGMP, and Drug Supply Chain Security Act requirements. The code shows insufficient recent activity directly supporting paliperidone procurement.